Consensus Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange 11:31:48 2023-12-01 am EST Intraday chart for Novartis AG 5-day change 1st Jan Change
85.38 CHF +0.31% -1.62% +2.14%

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History : Analyst Recommendations

637abaea2004f6dc2f83de5.du5d_BJHcQXH6jeMVBJx76FkvuWknELLgZjrRoEPUHg.Dpg7lUImP0ujhmS8IFw-hfUc-a3A_TOqyvCBPPFQYz8TiWzKWHc0cbCFDw~57e0ad78ff62acfb91bf7663be23df26
NOVARTIS AG : Deutsche Bank gives a Buy rating ZD
NOVARTIS : Oddo BHF confirms its recommendation after R&D day CF
NOVARTIS AG : Sell rating from Barclays ZD
NOVARTIS AG : Gets a Neutral rating from UBS ZD
NOVARTIS : price target maintained by Oddo BHF CF
NOVARTIS AG : Jefferies reaffirms its Buy rating ZD
NOVARTIS AG : Receives a Buy rating from Deutsche Bank ZD
Kepler Cheuvreux Lifts Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : Deutsche Bank remains its Buy rating ZD
Societe Generale Lowers Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS : Healthy Q3; guidance upgraded ‘again’ Alphavalue
NOVARTIS AG : UBS remains Neutral ZD
NOVARTIS AG : Jefferies gives a Buy rating ZD
NOVARTIS AG : Barclays maintains a Sell rating ZD
Novartis to Navigate Patent Expirations After Concluding Simplification, Berenberg Says MT
NOVARTIS AG : Berenberg sticks Neutral ZD
Redburn Atlantic Lowers Price Target on Novartis, Maintains Neutral Recommendation MT
Stifel Lowers Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : Jefferies keeps its Buy rating ZD
DZ Bank Lowers Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : JP Morgan sticks Neutral ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating ZD
NOVARTIS AG : Gets a Neutral rating from UBS ZD
Fitch Affirms Bausch Health, Bausch Health America's Ratings; Bausch + Lomb's Rating Maintained MT
NOVARTIS : Taking on board the Sandoz spin-off. Alphavalue
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
98.09USD
Average target price
105.39USD
Spread / Average Target
+7.45%
High Price Target
124.68USD
Spread / Highest target
+27.11%
Low Price Target
83.80USD
Spread / Lowest Target
-14.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

DEUTSCHE BANK RESEARCH Emmanuel Papadakis
BARCLAYS Emily Field
UBS Colin White
JEFFERIES Peter Welford
Kepler Capital Markets
Societe Generale
alphavalue Abhishek Raval
BERENBERG Kerry Holford
Redburn
Stifel Nicolaus
DZ Bank
JPMORGAN Richard Vosser
BNP Paribas
MORGAN STANLEY Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
GOLDMAN SACHS Keyur Parekh
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Berenberg Bank
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER Eric Le Berrigaud
LIBERUM CAPITAL Graham Doyle
BANK OF AMERICA (BOFA) Graham Parry
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer